enGene Holdings Inc. Warrants (ENGNW)
ENGNW Stock Price Chart
Explore enGene Holdings Inc. Warrants interactive price chart. Choose custom timeframes to analyze ENGNW price movements and trends.
ENGNW Company Profile
Discover essential business fundamentals and corporate details for enGene Holdings Inc. Warrants (ENGNW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
—
Employees
56.00
Website
https://www.engene.comCEO
Ronald H. W. Cooper
Description
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
ENGNW Financial Timeline
Browse a chronological timeline of enGene Holdings Inc. Warrants corporate events including earnings releases, dividend announcements, and stock splits.
ENGNW Stock Performance
Access detailed ENGNW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.